|
| 產(chǎn)地 | France |
| 品牌 | AntibodySystem |
| 保存條件 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -311°C long term. |
| 貨號(hào) | DHD68911 |
| 用途 | 類似物，陽(yáng)性對(duì)照抗體 |
| 應(yīng)用范圍 | 類似物，陽(yáng)性對(duì)照抗體 |
| 抗原來(lái)源 | Mammalian cells |
| 保質(zhì)期 | 1 year |
| 抗體名 | Research Grade Sotigalimab |
| 是否單克隆 | 是 |
| 克隆性 | 是 |
| 靶點(diǎn) | APX005M |
| 適應(yīng)物種 | Human |
| 形態(tài) | Liquid |
| 宿主 | 是 |
| 標(biāo)記物 | Unconjugate |
| 包裝規(guī)格 | 100ug |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | Unconjugate |
| 濃度 | 1mg/ml% |
| 免疫原 | Human |
| 是否進(jìn)口 | 是 |
Tags: 抗Sotigalimab抗體 supplier,抗Sotigalimab抗體 purchase,抗Sotigalimab抗體 manufacturer,抗Sotigalimab抗體 distributor,抗Sotigalimab抗體 cost,抗Sotigalimab抗體 buy,抗Sotigalimab抗體 for sale
Description
The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.
DHD68911
Humanized
Human
PBS buffer pH 7.4
2.54 mg/ml
>95%
Monoclonal
IgG1-Kappa
Research Grade Sotigalimab Biosimilar
Tumor necrosis factor receptor superfamily member 5,B-cell surface antigen CD40,Bp50,CD40L receptor,TNFRSF5,CDw40,CD40
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
Mammalian cells
P25942
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.
AntibodySystem由具有30多年蛋白抗體開發(fā)經(jīng)驗(yàn)的 創(chuàng)立于法國(guó),專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國(guó)斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點(diǎn)蛋白以及對(duì)照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。
普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。
如果您對(duì)我們的產(chǎn)品感興趣,請(qǐng)聯(lián)系027-65279366。
以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)
